Get the Stockscreener App
5.50
6.14%
-0.36
After Hours:
5.53
0.03
+0.55%
Tevogen Bio Holdings Inc stock is traded at $5.50, with a volume of 11,325.
It is down -6.14% in the last 24 hours and down -47.47% over the past month.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
See More
Previous Close:
$5.86
Open:
$5.905
24h Volume:
11,325
Relative Volume:
0.40
Market Cap:
$23.21M
Revenue:
-
Net Income/Loss:
$-26.28M
P/E Ratio:
-1.2823
EPS:
-4.2891
Net Cash Flow:
$-12.39M
1W Performance:
-2.83%
1M Performance:
-47.47%
6M Performance:
-71.52%
1Y Performance:
-90.83%
1-Day Range:
$5.43
$5.905
1-Week Range:
$5.43
$6.745
52-Week Range:
$4.1353
$71.00
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Name
Tevogen Bio Holdings Inc
Sector
Industry
Phone
646-807-8832
Address
15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN
Compare TVGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
5.50 | 24.73M | 0 | -26.28M | -12.39M | -4.2891 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-04-25 | Initiated | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Stock (TVGN) Latest News
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Enterprise value to EBIT forward of Tevogen Bio Holdings Inc. – NASDAQ:TVGN - TradingView
Enterprise value to EBIT forward of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Enterprise value to revenue forward of Tevogen Bio Holdings Inc. – NASDAQ:TVGN - TradingView
Enterprise value to revenue forward of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Tevogen Bio (NASDAQ: TVGN) registers 375,000 shares for resale by Patel Family - Stock Titan
Tevogen Bio Holdings Company Profile & Introduction - Moomoo
[EFFECT] Tevogen Bio Holdings Inc. SEC Filing - Stock Titan
Price to book forward of Tevogen Bio Holdings Inc. – NASDAQ:TVGN - TradingView
Price to sales forward of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Price to earnings forward of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Tevogen Bio Holdings Inc (TVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value to EBITDA forward of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Tevogen Bio Holdings Inc (TVGNW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tevogen Bio Holdings Inc (TVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Institutional Confidence - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tevogen Bio Holdings Inc (TVGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tevogen Bio Holdings Inc (TVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tevogen Bio Holdings Inc (TVGN) Institutional Confidence - TradingKey
Tevogen Bio Holdings Inc (TVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tevogen Bio Holdings Inc (TVGNW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tevogen Bio Holdings Inc (TVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tevogen Bio Holdings Inc (TVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tevogen Bio Holdings Inc (TVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tevogen Bio Holdings Inc. Q4 2025 Earnings: Narrower Loss Beats Expectations as Development Progress ContinuesROIC Trend Report - newsline.com
Tevogen Bio (TVGN) registers 375,000 shares for resale by Patel Family - Stock Titan
Tevogen Bio Q4 2025 Earnings: EPS Surprise Beat Amid Ongoing Operational ChallengesGeographic Revenue Trends - newsline.com
Tevogen Bio Warrants (TVGNW) Stall at $0.04 as Trading Remains FlatLow Vol ETF - newsline.com
Tevogen Announces Formation of a Healthcare Services Initiative - The Manila Times
Number of shareholders of Tevogen Bio Holdings Inc. – NASDAQ:TVGNW - TradingView
Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions - Quiver Quantitative
Tevogen weighs $100M in potential MSO, CRO revenue with new unit - Stock Titan
TVGN Q4 2025 Earnings: Narrowed Loss Per Share Exceeds Expectations, Shares RisePost-Earnings Reaction - newsline.com
Tevogen Bio Q4 2025 Earnings: EPS Surprise Beats Estimates Despite No Revenue, Shares RiseAnalyst Consensus Shift - newsline.com
TVGN Q4 2025 Earnings: Narrowed Loss Beats Expectations as Stock SurgesSlow Growth Warning - newsline.com
TEVOGEN BIO HOLDINGS INC (TVGN) Stock Chart - ChartMill
Why Is Tevogen Bio Holdings Inc. (TVGNW) Stock Down Today? - Meyka
Tevogen Bio Holdings Inc. (TVGN) Q4 2025 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline Advances - newsline.com
TVGN Q4 2025 Earnings: Narrower Loss Surprises as Tevogen Focuses on Pipeline ExecutionPost-Announcement Reaction - Město Břeclav
Tevogen Shares Drop After $100 Million Revenue Target; Deal Risk Eyed - Bez Kabli
Tevogen Bio Holdings Inc. Outlines Strategic Acquisition Initiatives Aiming for $100 Million in Annual Revenue - Quiver Quantitative
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ... - Caledonian Record
Tevogen outlines biotech, AI and healthcare services vision - Stock Titan
TVGNTevogen Bio Holdings Inc Stock Price and Quote - Finviz
Tevogen Bio Warrant (TVGNW) Holds at $0.04 with Modest UptickDividend Growth Stocks - newsline.com
Tevogen Bio Holdings Inc Stock (TVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tevogen Bio Holdings Inc Stock (TVGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flomenberg Neal | See Remarks |
Mar 13 '26 |
Sale |
6.40 |
501 |
3,206 |
76,940 |
| Flomenberg Neal | See Remarks |
Mar 10 '26 |
Sale |
7.75 |
19 |
147 |
77,893 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):